A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence

Rolley E. Johnson, Thomas Eissenberg, Maxine L Stitzer, Eric C Strain, Ira A. Liebson, George Bigelow

Research output: Contribution to journalArticle

Abstract

Large-scale placebo controlled clinical trials assessing the efficacy of medications for the treatment of drug dependence have generally been limited to alcohol, cocaine and nicotine dependent populations. The purpose of the present study was to assess the early (1-2 week) clinical effectiveness of buprenorphine versus placebo in an opioid dependent population. The study used a parallel-group design with a behavioral choice component to compare buprenorphine (a mu-opioid partial agonist) to placebo for the treatment of opioid dependence. Opioid dependent volunteer patients participated in a 14-day study to assess the effectiveness and patient acceptance of this new pharmacotherapy for the treatment of opioid dependence. Patients were randomly assigned to placebo (n = 60) or 2 mg (n = 60) or 8 mg (n = 30) daily sublingual buprenorphine. All doses were administered double-blind. On days 6-13 all patients could request a dose change, knowing that their new dose would be randomly chosen from the remaining 2 alternatives. Compared to placebo, patients given buprenorphine (independent of dose) showed greater time on initial dose, requested fewer dose changes, used less illicit opioids (assessed by urinalysis), and rated dose adequacy higher. These results demonstrate that a placebo controlled study with a behavioral choice component is an effective means of assessing the potential efficacy and acceptability of new pharmacotherapies for opioid dependence.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalDrug and Alcohol Dependence
Volume40
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Buprenorphine
Controlled Clinical Trials
Opioid Analgesics
Placebos
drug dependence
Drug therapy
nicotine
medication
Therapeutics
acceptance
alcohol
Drug Therapy
Urinalysis
Nicotine
Cocaine
Population
Group
Substance-Related Disorders
Volunteers
Alcohols

Keywords

  • Acceptability
  • Buprenorphine
  • Clinical trial
  • Efficacy
  • Placebo

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology
  • Toxicology
  • Medicine(all)
  • Behavioral Neuroscience
  • Health(social science)

Cite this

A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. / Johnson, Rolley E.; Eissenberg, Thomas; Stitzer, Maxine L; Strain, Eric C; Liebson, Ira A.; Bigelow, George.

In: Drug and Alcohol Dependence, Vol. 40, No. 1, 1995, p. 17-25.

Research output: Contribution to journalArticle

@article{03d99fb806c04d218e1f1b2b7c218538,
title = "A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence",
abstract = "Large-scale placebo controlled clinical trials assessing the efficacy of medications for the treatment of drug dependence have generally been limited to alcohol, cocaine and nicotine dependent populations. The purpose of the present study was to assess the early (1-2 week) clinical effectiveness of buprenorphine versus placebo in an opioid dependent population. The study used a parallel-group design with a behavioral choice component to compare buprenorphine (a mu-opioid partial agonist) to placebo for the treatment of opioid dependence. Opioid dependent volunteer patients participated in a 14-day study to assess the effectiveness and patient acceptance of this new pharmacotherapy for the treatment of opioid dependence. Patients were randomly assigned to placebo (n = 60) or 2 mg (n = 60) or 8 mg (n = 30) daily sublingual buprenorphine. All doses were administered double-blind. On days 6-13 all patients could request a dose change, knowing that their new dose would be randomly chosen from the remaining 2 alternatives. Compared to placebo, patients given buprenorphine (independent of dose) showed greater time on initial dose, requested fewer dose changes, used less illicit opioids (assessed by urinalysis), and rated dose adequacy higher. These results demonstrate that a placebo controlled study with a behavioral choice component is an effective means of assessing the potential efficacy and acceptability of new pharmacotherapies for opioid dependence.",
keywords = "Acceptability, Buprenorphine, Clinical trial, Efficacy, Placebo",
author = "Johnson, {Rolley E.} and Thomas Eissenberg and Stitzer, {Maxine L} and Strain, {Eric C} and Liebson, {Ira A.} and George Bigelow",
year = "1995",
doi = "10.1016/0376-8716(95)01186-2",
language = "English (US)",
volume = "40",
pages = "17--25",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence

AU - Johnson, Rolley E.

AU - Eissenberg, Thomas

AU - Stitzer, Maxine L

AU - Strain, Eric C

AU - Liebson, Ira A.

AU - Bigelow, George

PY - 1995

Y1 - 1995

N2 - Large-scale placebo controlled clinical trials assessing the efficacy of medications for the treatment of drug dependence have generally been limited to alcohol, cocaine and nicotine dependent populations. The purpose of the present study was to assess the early (1-2 week) clinical effectiveness of buprenorphine versus placebo in an opioid dependent population. The study used a parallel-group design with a behavioral choice component to compare buprenorphine (a mu-opioid partial agonist) to placebo for the treatment of opioid dependence. Opioid dependent volunteer patients participated in a 14-day study to assess the effectiveness and patient acceptance of this new pharmacotherapy for the treatment of opioid dependence. Patients were randomly assigned to placebo (n = 60) or 2 mg (n = 60) or 8 mg (n = 30) daily sublingual buprenorphine. All doses were administered double-blind. On days 6-13 all patients could request a dose change, knowing that their new dose would be randomly chosen from the remaining 2 alternatives. Compared to placebo, patients given buprenorphine (independent of dose) showed greater time on initial dose, requested fewer dose changes, used less illicit opioids (assessed by urinalysis), and rated dose adequacy higher. These results demonstrate that a placebo controlled study with a behavioral choice component is an effective means of assessing the potential efficacy and acceptability of new pharmacotherapies for opioid dependence.

AB - Large-scale placebo controlled clinical trials assessing the efficacy of medications for the treatment of drug dependence have generally been limited to alcohol, cocaine and nicotine dependent populations. The purpose of the present study was to assess the early (1-2 week) clinical effectiveness of buprenorphine versus placebo in an opioid dependent population. The study used a parallel-group design with a behavioral choice component to compare buprenorphine (a mu-opioid partial agonist) to placebo for the treatment of opioid dependence. Opioid dependent volunteer patients participated in a 14-day study to assess the effectiveness and patient acceptance of this new pharmacotherapy for the treatment of opioid dependence. Patients were randomly assigned to placebo (n = 60) or 2 mg (n = 60) or 8 mg (n = 30) daily sublingual buprenorphine. All doses were administered double-blind. On days 6-13 all patients could request a dose change, knowing that their new dose would be randomly chosen from the remaining 2 alternatives. Compared to placebo, patients given buprenorphine (independent of dose) showed greater time on initial dose, requested fewer dose changes, used less illicit opioids (assessed by urinalysis), and rated dose adequacy higher. These results demonstrate that a placebo controlled study with a behavioral choice component is an effective means of assessing the potential efficacy and acceptability of new pharmacotherapies for opioid dependence.

KW - Acceptability

KW - Buprenorphine

KW - Clinical trial

KW - Efficacy

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0028827422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028827422&partnerID=8YFLogxK

U2 - 10.1016/0376-8716(95)01186-2

DO - 10.1016/0376-8716(95)01186-2

M3 - Article

C2 - 8746920

AN - SCOPUS:0028827422

VL - 40

SP - 17

EP - 25

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -